AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2729161 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of participants with PPBG greater than 13 mmol/L
Number of subjects: 0
Study 31927654 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined prevention and early intervention (SPEI)
Number of subjects: 109
Study 31927654 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study 29028128 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI proton density fat fraction (PDFF)
Number of subjects: 169
Study 27777795 — intervention group
Group type: EXPERIMENTAL
Intervention: P-SIT (sprint-interval training with passive recovery)
Number of subjects: 62
Study 27777795 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (endurance training)
Number of subjects: 62
Study 27777795 — intervention group
Group type: EXPERIMENTAL
Intervention: A-SIT (sprint-interval training with active recovery)
Number of subjects: 62
Study 27777795 — intervention group
Group type: COMPARATOR
Intervention: CON (nonexercise control condition)
Number of subjects: 62
Study 25697600 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic load counting (GLC)
Number of subjects: 9
Study 25697600 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting (CC)
Number of subjects: 9
Study 23698160 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate enriched diet (200 μg)
Number of subjects: 149
Study 23698160 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MTHF (200 μg)
Number of subjects: 149
Study 23698160 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (200 μg)
Number of subjects: 149
Study 23698160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 20647200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily for 52 weeks
Number of subjects: 3182
Study 20647200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin continued in year 2
Number of subjects: 3182
Study 20647200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3182
Study 20647200 — intervention group
Group type: COMPARATOR
Intervention: Placebo continued in year 2
Number of subjects: 3182
Study 20647200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3182
Study 20647200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 3182
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 0
Study 18973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 18973730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15998758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-than-usual target blood pressure
Number of subjects: 0
Study 12517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of reliever medications
Number of subjects: 638
Study 12517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of controller medications
Number of subjects: 638
Study 12517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control adequacy
Number of subjects: 638
Study 10574652 — intervention group
Group type: COMPARATOR
Intervention: Butter (B)
Number of subjects: 30
Study 10574652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified mixture (IM) of butter, medium-chain triacylglycerol (MCT), and safflower oils
Number of subjects: 30
Study 10160460 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal Detector Device (EDD)
Number of subjects: 5
Study 10160460 — intervention group
Group type: COMPARATOR
Intervention: Airway managers (control)
Number of subjects: 5
Study 1715450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and triamterene
Number of subjects: 0
Study 1715450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 1715450 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 1715450 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa or placebo
Number of subjects: 0
Study 7137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 100 mg sustained-release preparation
Number of subjects: 0
Study 7137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 50 mg combined with antihistamine
Number of subjects: 0
Study 7137522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7137522 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine (DHE) 5 mg
Number of subjects: 0
Study 7137522 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA (100 mg) and combined preparation containing PPA (50 mg) taken twice a day
Number of subjects: 0
Study 30527555 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardix® (liquid-based hyaluronic acid and carboxymethyl cellulose solution)
Number of subjects: 488
Study 30527555 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm® (sodium hyaluronate-based bioresorbable membrane)
Number of subjects: 488
Study 30527555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-adhesive)
Number of subjects: 488
Study 30527555 — intervention group
Group type: COMPARATOR
Intervention: Seprafilm® vs Control
Number of subjects: 488
Study 30527555 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardix® vs Seprafilm®
Number of subjects: 488
Study 28599762 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Co-teaching (ICT)
Number of subjects: 100
Study 28599762 — intervention group
Group type: COMPARATOR
Intervention: Conventional Teaching (CT)
Number of subjects: 100
Study 27577112 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS (20 g sachet per day during pregnancy and first 6 months of lactation)
Number of subjects: 2189
Study 27577112 — intervention group
Group type: COMPARATOR
Intervention: Control groups (multiple micronutrients during pregnancy and lactation or iron and folic acid during pregnancy and calcium during lactation)
Number of subjects: 2189
Study 25188375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bolus delivered with meal (n=51)
Number of subjects: 53
Study 25188375 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bolus delivered 15 min prior to meal (n=40)
Number of subjects: 53
Study 25188375 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-bolus of 30% delivered with meal (n=40)
Number of subjects: 53
Study 25188375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus purposely omitted (n=46)
Number of subjects: 53
Study 23023460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatrician in triage (PIT)
Number of subjects: 6579
Study 23023460 — intervention group
Group type: COMPARATOR
Intervention: Conventional registered nurse‐driven triage (control)
Number of subjects: 6579
Study 19462490 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake
Number of subjects: 4919
Study 19462490 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary potassium intake
Number of subjects: 4919
Study 17098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-interview (CASI)
Number of subjects: 611
Study 17098771 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview (FTFI)
Number of subjects: 611
Study 16269298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric operation (not specified dosage or duration)
Number of subjects: 248
Study 12162474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg x 3, q4-6h)
Number of subjects: 174
Study 12162474 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 174
Study 12162474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 10786514 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 114
Study 10786514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight management program)
Number of subjects: 114
Study 8522738 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor carpi ulnaris to extensor digitorum communis tendon transfer
Number of subjects: 6
Study 8522738 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 volunteers)
Number of subjects: 6
Study 1972947 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% calcium mupirocin ointment after tincture of iodine
Number of subjects: 218
Study 1972947 — intervention group
Group type: COMPARATOR
Intervention: tincture of iodine (control)
Number of subjects: 218
Study 7439516 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 16
Study 7439516 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 16
Study 7439516 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose combination of slow-release aminophylline and salbutamol
Number of subjects: 16
Study 31196470 — intervention group
Group type: EXPERIMENTAL
Intervention: Port site resection (PSR)
Number of subjects: 123
Study 31196470 — intervention group
Group type: COMPARATOR
Intervention: No port site resection (No-PSR)
Number of subjects: 123
Study 29798201 — intervention group
Group type: EXPERIMENTAL
Intervention: Binglianqingye Spray
Number of subjects: 360
Study 29798201 — intervention group
Group type: COMPARATOR
Intervention: Jinsangzi Tablet
Number of subjects: 360
Study 29798201 — intervention group
Group type: COMPARATOR
Intervention: Jinhoujian Spray
Number of subjects: 360
Study 27108410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review (PMC) at study start (T-0) and after 28 weeks (T-28)
Number of subjects: 450
Study 27108410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review (PMC)
Number of subjects: 450
Study 27108410 — intervention group
Group type: COMPARATOR
Intervention: Control group received only a PMC at T-28
Number of subjects: 450
Study 24354731 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically modified vulvas
Number of subjects: 97
Study 24354731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmodified vulvas
Number of subjects: 97
Study 24354731 — intervention group
Group type: COMPARATOR
Intervention: No images (Control)
Number of subjects: 97
Study 22781864 — intervention group
Group type: EXPERIMENTAL
Intervention: High life stress and DRD4 7 + R allele
Number of subjects: 399
Study 22781864 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Stress × DRD4 Status interaction
Number of subjects: 399
Study 21071989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 284
Study 21071989 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 284
Study 18421919 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBCT) for 120-180 seconds at temperatures between -110°C and -160°C, 15 treatments over 3 weeks.
Number of subjects: 60
Study 18421919 — intervention group
Group type: COMPARATOR
Intervention: Standard psychopharmacological treatment (not specified)
Number of subjects: 60
Study 15206496 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg/day
Number of subjects: 22
Study 15206496 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/day
Number of subjects: 22
Study 15206496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg/day enalapril and 50 mg/day losartan)
Number of subjects: 22
Study 15206496 — intervention group
Group type: COMPARATOR
Intervention: Double-dose monotherapy (20 mg/day enalapril or 100 mg/day losartan)
Number of subjects: 22
Study 15206496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (enalapril and losartan)
Number of subjects: 22
Study 11591494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (transdermal administration)
Number of subjects: 20
Study 11591494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9673474 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (stages 2, 3, and 4)
Number of subjects: 45
Study 9673474 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects and stage 0 and stage 1 hypertensive retinopathy patients
Number of subjects: 45
Study 8207039 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters coated with CH alone
Number of subjects: 30
Study 8207039 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters coated with CH with or without HEP
Number of subjects: 30
Study 8207039 — intervention group
Group type: COMPARATOR
Intervention: Catheters coated with CH/HEP
Number of subjects: 30
Study 8207039 — intervention group
Group type: COMPARATOR
Intervention: Catheters coated with CH
Number of subjects: 30
Study 2914008 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 0
Study 2914008 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control
Number of subjects: 0
Study 2914008 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 0
Study 2914008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2914008 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 1102260 — intervention group
Group type: EXPERIMENTAL
Intervention: Methocarbamol (1500 mg. q.d.s.)
Number of subjects: 59
Study 1102260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31545799 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide Choline Controlled-Release Tablets (DCCR)
Number of subjects: 13
Study 28260689 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter filled with 30mL
Number of subjects: 174
Study 28260689 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter filled with 60mL
Number of subjects: 174
Study 28260689 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter filled with 30mL and 60mL
Number of subjects: 174
Study 25126675 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, DMG, Hamburg, Germany)
Number of subjects: 20
Study 21824756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with water (CW)
Number of subjects: 18
Study 21824756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with milk (CM)
Number of subjects: 18
Study 21824756 — intervention group
Group type: EXPERIMENTAL
Intervention: Only milk (M)
Number of subjects: 18
Study 21296261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi Qigong (TCQ) program, two 60-min sessions each week for three months
Number of subjects: 206
Study 21296261 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing techniques combined with walking as an exercise
Number of subjects: 206
Study 21296261 — intervention group
Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 206
Study 19964499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-mediated post-stroke rehabilitation using haptic/graphic error augmentation
Number of subjects: 0
Study 16579706 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium healing caps
Number of subjects: 5
Study 16579706 — intervention group
Group type: COMPARATOR
Intervention: Zirconium oxide healing caps
Number of subjects: 5
Study 16579706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5
Study 12928471 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 0
Study 12928471 — intervention group
Group type: EXPERIMENTAL
Intervention: lipoprotein(a)
Number of subjects: 0
Study 12928471 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrinogen
Number of subjects: 0
Study 12928471 — intervention group
Group type: EXPERIMENTAL
Intervention: homocysteine
Number of subjects: 0
Study 16505324 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 dihydrate 30 mg for 1 week followed by 40 mg for 5 weeks
Number of subjects: 70
Study 10575563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (250 b.i.d. for 12 months)
Number of subjects: 33
Study 10575563 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 patients)
Number of subjects: 33
Study 10575563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Number of subjects: 33
Study 8916695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided fine needle aspiration
Number of subjects: 278
Study 8916695 — intervention group
Group type: COMPARATOR
Intervention: Simple observation
Number of subjects: 278
Study 2006723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 ml 0.25% every 4 h)
Number of subjects: 10
Study 2006723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus epinephrine 1:200,000
Number of subjects: 10
Study 2006723 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 10
Study 2006723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (with epinephrine)
Number of subjects: 10
Study 2006723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 10
Study 7096279 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin HCl (50 mg h.s.)
Number of subjects: 50
Study 7096279 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1000 mg/day in divided doses)
Number of subjects: 50
Study 31071047 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-DHD (three-dimensional printed dynamic hand device) used twice a week for four weeks, followed by a two-week home program
Number of subjects: 10
Study 31071047 — intervention group
Group type: COMPARATOR
Intervention: Control group (only task-oriented approach without 3D-DHD)
Number of subjects: 10
Study 28828866 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play intervention
Number of subjects: 8
Study 28828866 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 26956164 — intervention group
Group type: EXPERIMENTAL
Intervention: Three randomly ordered slightly different 140 character or less messages containing a short URL to the freely accessible summary page sent on specific times on one single day
Number of subjects: 170
Study 26956164 — intervention group
Group type: COMPARATOR
Intervention: No messaging
Number of subjects: 170
Study 24324045 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (vitamin C, vitamin E, α‐lipoic acid)
Number of subjects: 30
Study 24324045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22877086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 91
Study 22877086 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 91
Study 22877086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) + Methylphenidate
Number of subjects: 91
Study 19417110 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (mean dose 114 +/- 41 mg/day)
Number of subjects: 27
Study 19417110 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 27
Study 19417110 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor therapy
Number of subjects: 27
Study 17413835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with tailored assessment and interventions for heel pressure ulcer prevention.
Number of subjects: 242
Study 17413835 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care without tailored interventions.
Number of subjects: 242
Study 17413835 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial heel pressure relief device used in the intervention group.
Number of subjects: 242
Study 15336471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 350 mg IV
Number of subjects: 64
Study 15336471 — intervention group
Group type: COMPARATOR
Intervention: Metamizol sodium 2,500 mg IV
Number of subjects: 64
Study 11245323 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 39
Study 11245323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 39
Study 9730125 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pump (A-V Impulse System) for 7 days
Number of subjects: 290
Study 9730125 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin 40 mg daily) for 7 days
Number of subjects: 290
Study 9730125 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pump
Number of subjects: 290
Study 9730125 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 290
Study 7973479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 42
Study 7973479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30837573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H2O2) whitening products
Number of subjects: 0
Study 30837573 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% H2O2 bleaching
Number of subjects: 0
Study 30837573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of H2O2
Number of subjects: 0
Study 28461256 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg) with carboplatin/paclitaxel
Number of subjects: 158
Study 28461256 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin/paclitaxel
Number of subjects: 158
Study 25407380 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (aerobic, strength, and balance exercises)
Number of subjects: 69
Study 25407380 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (strength exercises using six machines)
Number of subjects: 69
Study 25407380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 22858264 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-based psychoeducational group (BDG) intervention consisting of 12 weekly 90-min sessions teaching DBT skills, mindfulness techniques, and general BD psychoeducation.
Number of subjects: 26
Study 22858264 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 26